No Data
No Data
Tarsus Pharmaceuticals Price Target Raised to $44.00/Share From $30.00 by Jefferies
Tarsus Pharmaceuticals Price Target Raised to $44.00/Share From $30.00 by Jefferies
Tarsus to Participate at Upcoming Investor Conferences
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for
Tarsus Introduces "Mite Party" Campaign for XDEMVY (Lotilaner Ophthalmic Solution) 0.25% to Educate Consumers About Demodex Blepharitis
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25 million eye care
Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) defied analyst predictions to release its full-year results, which were ahead of market expectations. Revenues of US$17m beat estimates by a substantial
Tarsus Pharmaceuticals Stock Dips After Pricing $100M Securities Offering
Tarsus Offering Is Expected to Close March 5 >TARS
Tarsus Offering Is Expected to Close March 5 >TARS
No Data